First Commonwealth Financial Corp PA Purchases 1,198 Shares of Johnson & Johnson (NYSE:JNJ)

First Commonwealth Financial Corp PA boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.7% during the 4th quarter, Holdings Channel reports. The fund owned 9,922 shares of the company’s stock after buying an additional 1,198 shares during the period. First Commonwealth Financial Corp PA’s holdings in Johnson & Johnson were worth $1,435,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $4,390,037,000. Raymond James Financial Inc. purchased a new position in Johnson & Johnson in the fourth quarter valued at about $1,339,878,000. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after purchasing an additional 1,772,706 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after buying an additional 1,729,281 shares during the last quarter. Finally, Amundi grew its position in shares of Johnson & Johnson by 16.2% in the 4th quarter. Amundi now owns 11,930,183 shares of the company’s stock worth $1,698,984,000 after buying an additional 1,660,458 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Raymond James decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday. Bank of America lowered their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Nine analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $171.78.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $153.95 on Thursday. The stock has a market cap of $371.00 billion, a PE ratio of 23.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The business has a 50-day simple moving average of $159.40 and a 200-day simple moving average of $155.10. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.38%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.